Podcasts about thoracic surgery

Journal of Clinical Oncology (JCO) Podcast

Play Episode Listen Later Aug 25, 2025 30:04

A silent danger lurks within the descending thoracic aorta. While most Type B aortic dissections are managed medically, up to half of these patients will either require life-saving surgery or die within just five years. So how do we separate those who will quietly recover from those on the edge of catastrophe? How do we protect the spinal cord, bowel, and limbs from the devastating consequences of malperfusion? Join the University of Michigan Department of Vascular Surgery as they tackle the high-stakes decisions behind managing this unpredictable disease—where timing is critical, interventions are evolving, and lives hang in the balance. Hosted by the University of Michigan Department of Vascular Surgery: · Robert Beaulieu, Program Director · Frank Davis, Assistant Professor of Surgery · Luciano Delbono, PGY-5 House Officer · Andrew Huang, PGY-4 House Officer · Carolyn Judge, PGY-2 House Officer Learning Objectives: 1. Discuss general approach to diagnosis and management of TBAD. 2. Identifying high-risk features in uncomplicated TBAD and understanding their role in determining the need for surgical management. 3. Review endovascular techniques for managing malperfusion of the limbs, viscera, and spinal cord and discuss associated decision making. References: Authors/Task Force Members, Czerny, M., Grabenwöger, M., Berger, T., Aboyans, V., Della Corte, A., Chen, E. P., Desai, N. D., Dumfarth, J., Elefteriades, J. A., Etz, C. D., Kim, K. M., Kreibich, M., Lescan, M., Di Marco, L., Martens, A., Mestres, C. A., Milojevic, M., Nienaber, C. A., … Hughes, G. C. (2024). EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic Organ. The Annals of Thoracic Surgery, 118(1), 5–115. https://doi.org/10.1016/j.athoracsur.2024.01.021 de Kort, J. F., Hasami, N. A., Been, M., Grassi, V., Lomazzi, C., Heijmen, R. H., Hazenberg, C. E. V. B., van Herwaarden, J. A., & Trimarchi, S. (2025). Trends and Updates in the Management and Outcomes of Acute Uncomplicated Type B Aortic Dissection. Annals of Vascular Surgery, S0890-5096(25)00004-4. https://doi.org/10.1016/j.avsg.2024.12.060 Eidt, J. F., & Vasquez, J. (2023). Changing Management of Type B Aortic Dissections. Methodist DeBakey Cardiovascular Journal, 19(2), 59–69. https://doi.org/10.14797/mdcvj.1171 Lombardi, J. V., Hughes, G. C., Appoo, J. J., Bavaria, J. E., Beck, A. W., Cambria, R. P., Charlton-Ouw, K., Eslami, M. H., Kim, K. M., Leshnower, B. G., Maldonado, T., Reece, T. B., & Wang, G. J. (2020). Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for type B aortic dissections. Journal of Vascular Surgery, 71(3), 723–747. https://doi.org/10.1016/j.jvs.2019.11.013 MacGillivray, T. E., Gleason, T. G., Patel, H. J., Aldea, G. S., Bavaria, J. E., Beaver, T. M., Chen, E. P., Czerny, M., Estrera, A. L., Firestone, S., Fischbein, M. P., Hughes, G. C., Hui, D. S., Kissoon, K., Lawton, J. S., Pacini, D., Reece, T. B., Roselli, E. E., & Stulak, J. (2022). The Society of Thoracic Surgeons/American Association for Thoracic Surgery Clinical Practice Guidelines on the Management of Type B Aortic Dissection. The Annals of Thoracic Surgery, 113(4), 1073–1092. https://doi.org/10.1016/j.athoracsur.2021.11.002 Papatheodorou, N., Tsilimparis, N., Peterss, S., Khangholi, D., Konstantinou, N., Pichlmaier, M., & Stana, J. (2025). Pre-Emptive Endovascular Repair for Uncomplicated Type B Dissection—Is This an Option? Annals of Vascular Surgery, S0890-5096(25)00007-X. https://doi.org/10.1016/j.avsg.2025.01.003 Trimarchi, S., Gleason, T. G., Brinster, D. R., Bismuth, J., Bossone, E., Sundt, T. M., Montgomery, D. G., Pai, C.-W., Bissacco, D., de Beaufort, H. W. L., Bavaria, J. E., Mussa, F., Bekeredjian, R., Schermerhorn, M., Pacini, D., Myrmel, T., Ouzounian, M., Korach, A., Chen, E. P., … Patel, H. J. (2023). Editor's Choice - Trends in Management and Outcomes of Type B Aortic Dissection: A Report From the International Registry of Aortic Dissection. European Journal of Vascular and Endovascular Surgery: The Official Journal of the European Society for Vascular Surgery, 66(6), 775–782. https://doi.org/10.1016/j.ejvs.2023.05.015 Writing Committee Members, Isselbacher, E. M., Preventza, O., Hamilton Black Iii, J., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., Collins, T. J., DeAnda, A., Fanola, C. L., Girardi, L. N., Hicks, C. W., Hui, D. S., Jones, W. S., Kalahasti, V., … Woo, Y. J. (2022). 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 80(24), e223–e393. https://doi.org/10.1016/j.jacc.2022.08.004 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

JCO Article Insights: Lymph Node Dissection for Lung Cancer

Play Episode Listen Later Aug 25, 2025 21:49

In this JCO Article Insights episode, Dr. Joseph Matthew interviews authors Dr. Yang Zhang and Dr. Haiquan Chen about their recently published JCO article, "Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma" TRANSCRIPT Joseph Mathew: Welcome to the Journal of Clinical Oncology Article Insights episode for the August issue of the JCO. This is Joseph Mathew, editorial fellow for JCO, and today, it is my pleasure to have with us Dr. Haiquan Chen and Dr. Yang Zhang, authors of the recently published manuscript, "Phase 3 Study of Mediastinal Lymph Node Dissection for Ground-Glass Opacity-Dominant Lung Adenocarcinoma," which we will be discussing today. Dr. Chen is the Director of the Institute of Thoracic Oncology at Fudan University and the Chief of Thoracic Surgery at Fudan University Shanghai Cancer Center, where he is also the Head of Thoracic Oncology MDT and the Director of the Lung Cancer Center. Dr. Chen is a surgeon-scientist and a pioneer in developing individualized surgical strategies for early-stage non-small cell lung cancer. Dr. Zhang is a surgical oncologist and a member of the team which Dr. Chen leads at the Fudan University Shanghai Cancer Center. Welcome Dr. Chen and Dr. Zhang. Thank you very much for accepting our invitation and joining us today as part of this podcast episode. To summarize the salient points, this study presented the interim analysis of a multi-center, open-label, non-inferiority, randomized controlled trial investigating the necessity of systematic mediastinal lymph node dissection at the time of segmentectomy or lobectomy in patients with clinical stage T1N0M0 ground-glass opacity-dominant invasive lung adenocarcinoma, as defined by a consolidation-to-tumor ratio of 0.5 or less on thin-section computed tomography and a maximum tumor diameter of 3 cm or less. Eligible participants with intraoperatively confirmed invasive adenocarcinoma on frozen section analysis were randomized to either the systematic mediastinal lymph node dissection arm or to no mediastinal lymph node dissection. In the latter experimental group, mediastinal lymph nodes comprising the N2 nodal stations were not dissected, and the hilar nodes were variably addressed at the discretion of the operating surgeon. The primary endpoint of the trial was disease-free survival at 3 years. Secondary endpoints included perioperative outcomes, the status of lymph node metastasis in the systemic lymph node dissection arm, and 3-year overall survival. Before the trial reached its accrual target, a pre-planned interim safety analysis set for the time point when enrollment reached 300 patients was performed. It was noted that while none of the patients in either arm had nodal metastasis on postoperative pathological evaluation, lymph node dissection-related intraoperative and postoperative complications were more commonly observed in the systematic lymph node dissection arm, including one life-threatening episode of massive bleeding. Since this met the predefined criteria for trial termination, and in accordance with the principle of non-maleficence, further recruitment was stopped and the trial terminated. Although the 3-year disease-free survival and the overall survival for the enrolled patients were comparable, operative outcomes, including the duration of surgery, blood loss, chest tube duration, length of postoperative stay, and the rate of clinically significant complications, were significantly lower in the experimental arm compared with the systematic lymph node dissection group. The authors concluded that for well-selected patients, mediastinal nodal dissection could be omitted without adversely affecting oncological outcomes, representing a significant shift in current surgical practice, given that guidelines the world over recommend systematic lymph node dissection or sampling for all invasive lung cancers. In summary, this study addressed a clinically relevant question with regard to the extent of nodal dissection, especially in the light of recent evidence recommending less extensive parenchymal dissections for early-stage non-small cell lung cancer, with the findings suggesting that invasive lung adenocarcinoma associated with ground-glass opacities of consolidation-to-tumor ratio up to 0.5 was an excellent predictor of tumor biology, and in clinical T1N0M0 lesions, a reliable predictor of negative mediastinal lymph node involvement. So Dr. Chen and Dr. Zhang, could you tell us some more about what led you to do this research and the challenges which you faced while recruiting patients for this trial? Dr. Yang Zhang: Dr. Mathew, thank you for your summary. The current clinical guidelines recommend systematic lymph node dissection or sampling for every patient with early-stage lung cancer, regardless of their lymph node status. And in our clinical practice, we observe that this procedure causes a lot of surgical complications including chylothorax and recurrent laryngeal nerve injury. Furthermore, dissecting the tumor-draining lymph nodes actually may potentially damage the body's anti-tumor immunity. So, Dr. Chen proposed the concept of selective lymph node dissection, which we aimed to dissect the metastatic lymph nodes, while at the same time we try to preserve as many uninvolved lymph nodes as possible. So previously, we have conducted a series of retrospective studies to identify reliable predictors of nodal negative status in certain mediastinal zones, and we have performed a prospective observational phase 2 clinical trial to validate that the six criteria we proposed are 100% in predicting node-negative status. And this forms the basis for our phase 3 clinical trial. Dr. Haiquan Chen: This trial is only one of the series of trials. The meaning of this trial you already said. And for a long time, from the surgeon's point of view, we considered minimally invasive surgery. It minimizes the size of the incision and minimizes the number of the holes we made. So, the true and the high-impact of minimally invasive, we make a concept of minimal dissection, that means organ-level minimally invasive. So we proposed the concept of minimally invasive 3.0, that means minimal incision, minimal dissection (that means organ-level minimal), and systemic minimally invasive. So at first, we judged from the point of minimally invasive surgery. As long as immunotherapy is widely used in the clinical practice, we know immunotherapy, that means you use drugs to stimulate and activate the lymph node site. If we dissect all the metastatic lymph nodes, cut them out, how can we restimulate that lymph node site? So, from minimally invasive trauma and second, from the functional aspect, to try to save as many uninvolved lymph nodes as possible. Joseph Mathew: Thank you, Dr. Chen. That's a very interesting concept that you alluded to even in the discussion of this paper, as to the potential role of the non-metastatic lymph nodes as immune reservoirs. So, coming back to this paper, were there any challenges which you faced while recruiting patients for this trial? Dr. Haiquan Chen: The criteria is very clear. That means invasive adenocarcinoma, that means most of the centimeter is 3.0 centimeter and also CTR ratio less than 0.5. And we can see that, you know, we did study about that. Even the invasive component of the subsolid nodule, it's bigger than the solid part. That means even the pure GGO, we can find out that there's still some invasive component. From this point of view, pure GGO and subsolid GGO, from this part of invasive carcinoma, that means it's a special clinical subtype that we, from retrospective study and also prospective study, we find out this group of patients, there are no mediastinal lymph node metastasis. So I think it's very important for this kind of group that we can avoid doing the mediastinal lymph node dissection. And we can do organ-level minimally invasive surgery. And also, we try to keep the patient's immune function as normal as possible. Dr. Yang Zhang: Well, Dr. Mathew, we believe that the biggest challenge when we are enrolling these patients is that there needs to be a paradigm shift in the mind because systematic lymph node dissection has long been the standard of care. And some patients may misunderstand. Before the enrollment, we have to give them informed consent, but if the patient hears that they may be enrolled in the no-lymph-node-dissection group, they may feel that they do not receive radical, curative-intent surgery. So we believe, as Dr. Chen has said, after the release of our results, the no-lymph-node dissection may be incorporated in the future guideline for those patients without lymph node involvement, we can just omit the lymph node dissection. Joseph Mathew: The study described two pre-planned interim points during the course of subject enrollment when the data was analyzed. So Dr. Chen and Dr. Zhang, could you please explain a little more about these two interim points of analysis that were planned and the rationale behind it? Dr. Yang Zhang: When conducting this trial, we have two concerns. One is if there is any lymph node metastasis, there may be omission of metastatic lymph nodes not dissected in the no-lymph-node-dissection group. And there is another concern is that if all these lymph nodes are uninvolved, then dissecting these lymph nodes may cause life-threatening complications. So, we set the 150 interim analysis to ensure that there is no lymph node involvement in this group. And the other early termination criteria is set because if there is no lymph node involvement found in both groups, then a severe complication which is life-threatening is unacceptable because it threatens the patient's safety. Joseph Mathew: So, although you did briefly allude to in the paper, what was the basis for selecting DFS as the primary endpoint when the objective of this trial was to assess nodal involvement in this subset of tumors? Dr. Yang Zhang: Well, previously, we have done a series of retrospective studies and one prospective phase 2 trial. And in these studies, we have identified that GGO-dominant lung adenocarcinoma, even if it's invasive, it has no lymph node involvement. So this phase 3 trial was primarily designed to compare the survival outcomes. But as the trial went on, as Dr. Chen has concerns that if the patients have no lymph node metastasis at all, it may be unfair to dissect the lymph nodes for patients enrolled in the systematic lymph node dissection group. So there is one life-threatening complication that happens due to dissecting the lymph nodes and injury to the superior vena cava, which leads to massive bleeding. It is at this point that we decided to terminate this trial for patient safety concerns. Joseph Mathew: Yeah, that's a very fair point. So you made sure that the ethical considerations were kept intact. So another point was, there was a mention in the study of the historical data from your institution suggesting a 3-year disease-free survival of 96.6% for patients with clinical T1N0M0 ground-glass opacity-dominant invasive lung adenocarcinoma. So could you please elaborate on the patterns of recurrence which you noted for this group of patients who had developed a recurrence? Dr. Haiquan Chen: Yeah, I think over 90% 3-year DFS, that's the least. From our retrospective data for this kind of group of patients, their DFS is so good. To the best of my knowledge, almost 100%. So this is very conservative, 94, 90% is very conservative. I think the trial eventually would have been positive. It's a special clinical subtype, even for invasive adenocarcinoma, their prognosis is much better than the other type of invasive adenocarcinoma. Joseph Mathew: So this question may be slightly outside the purview of this study, but in your clinical practice, would you advocate either segmentectomy or lobectomy for all patients meeting the trial criteria, that is, lesions measuring 3 cm or less with a CTR of up to 0.5? Or is there a subgroup of patients you would recommend a wedge dissection for? Dr. Haiquan Chen: I think CTR ratio is one parameter and also the location is another very important parameter. So we put it together to make a decision, the patient should do a lobectomy or segmentectomy. Even for an ongoing trial, for even the patient, invasive adenocarcinoma, we can do in the right location, even wedge, it can achieve enough negative margin in the ongoing trial to verify the comparable result for the patient, we can do the wedge dissection. So not just the CTR ratio, that's not the only parameter to make a decision on what kind of procedure we'll do. Joseph Mathew: Yeah, great point, Dr. Chen. So from my perspective, this study was a well-designed, randomized control trial based on a relevant and clinically valid research question. So what, in your opinion, are the main strong points of this study? Dr. Yang Zhang: We believe that this study represents the first randomized clinical trial published, yet, regarding the topic of selective lymph node dissection. It basically offers the highest level of evidence. We believe our results should be incorporated in the future clinical guideline. Joseph Mathew: Given the increasing incidence of these lesions, I think it was- a randomized control trial in this arena was much awaited. And the other point is that GGO-dominant lung adenocarcinomas, the specific clinical guidelines are not very clear. So I think your study brought out that lymph node dissection for these tumors which satisfy the eligibility criteria could be omitted safely. Important consideration here is that the conclusions of the trial were based on an interim analysis, and this analysis was not planned for an early assessment of the primary endpoint. In other words, the study was not adequately powered to detect a significant difference in DFS at 3 years. So Dr. Chen and Dr. Zhang, what do you perceive are the most important limitations of this study which you feel should be addressed in future research? Dr. Haiquan Chen: So the surgery now is more individualized. I think the surgery from the last two decades, from the maximum tolerable intervention to minimum effective treatment, there's a big shift. So I think that the consensus, we can preserve normal lung parenchyma as much as possible. For the lymph nodes, I think that the big shift, we should shift it to keep as many as uninvolved lymph nodes as possible. So that's very important, not just to reduce the intraoperative trauma, but also to keep the immune environment as normal as possible. Joseph Mathew: Another point was the limited long-term follow-up data to determine the actual impact of omitting lymph node dissection on local-regional disease control. So is any future follow-up planned to assess the long-term survival outcomes for the 302 patients which were enrolled in this trial? Dr. Haiquan Chen: Yeah, I think that's very important for us. This trial we terminated just because if we keep the trial going, it's unfair for the mediastinal lymph node dissection group. We tried to just stop here, and we shifted to the single-arm trial. So, 2 or 3 years, this trial and another trial, they will give our final result to demonstrate more if selective mediastinal lymph nodes have a better result than ever before. And we will support the mediastinal lymph node dissection. That's one way. And the American College just asked me, how can we put this policy into clinical practice in the United States? Because most of the patients they meet have solid tumors. So we have another trial, try to figure out how we can make sure before and intraoperative the lymph node status is negative or positive, and then we can solve that problem and put this policy into clinical practice in the Western society. Joseph Mathew: Great. So that would be something we should all be looking forward to. So, this brings me to the final point of discussion on future research in this field. Dr. Chen, you commented in the paper that future studies should focus on improving the reproducibility of CTR evaluation. What are your thoughts on this subject? Dr. Haiquan Chen: The CTR ratio, the concept from the JCOG 0201, just a concept from that prospective study, the phase 2 study, only subgroup analysis they give the concept of CTR ratio and the diameter. How can we reproduce? In our group and also I believe in Japan and in China, in Korea, and in our daily practice, I think CTR ratio is not a big issue. There are two very important things. One, you make sure the CTR ratio, not in a common CAT scan, but in a high-resolution CAT scan. So the imaging, that's the first thing. And the second, not from the single section and a two or three section, you make sure that your calculation is accurate. That's not just the single section, you make sure that you got the conclusion, the CTR ratio is the same number. We make sure that totally we, from the top to the bottom of the whole lesion, we make sure that the CTR ratio is accurate. Joseph Mathew: Thank you, Dr. Chen. I think that would involve training our radiologists also to be aware of the CTR ratio and how it should be interpreted. So another very interesting concept which you had alluded to in the discussion was the potential role of non-metastatic lymph nodes as immune reservoirs. So how do you think we could preserve these nodes and do you think sentinel node biopsies would play a role in future? Dr. Yang Zhang: Actually, Dr. Chen has also led some basic research on this topic. We are investigating the immunological role of the tumor-draining lymph nodes. And our preliminary results have already shown that the tumor-draining lymph nodes of lung cancer, especially those uninvolved lymph nodes, have a vital role in the anti-tumor immunity and also effective response to the current anti-PD-1 immunotherapy. In the future, we believe that by incorporating our clinical evidence and those findings from our basic research, we will be able to provide very strong rationale to support selective lymph node dissection. Joseph Mathew: So lastly, what are the questions that still remain to be answered and what do you perceive as the next step in this field? Dr. Haiquan Chen: I think for the lung cancer surgery, especially for the cT1N0M0, they are more individualized. We can, based on the patient, the location, the CTR ratio, we can do wedge dissection, or segmentectomy, or lobectomy. For the lymph node dissection, we can do no mediastinal lymph node dissection or selective, only to dissect the positive one, or we have to do the systemic mediastinal lymph node dissection. So we can see there are too many combinations. So in the near future, for the surgery perspective, we have it more individualized. In the future, we just try to make sure we do not cut as many as possible. We just make sure that we can avoid over-diagnosis or overtreatment or over-dissected. I think that in the near future, that goal will come true. Joseph Mathew: That's a great point, Dr. Chen. So that would be something also for the thoracic oncology community to work towards. This wraps up today's episode of JCO Article Insights. Dr. Chen and Dr. Zhang, thank you very much for taking the time to join us today in what has been a very insightful session. Dr. Haiquan Chen: Thank you. Dr. Yang Zhang: Thanks. Joseph Mathew: To our audience, thank you for listening. Please stay tuned for more interviews and articles, summaries, and be sure to leave us your comments and ratings. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Journal Review in Thoracic Surgery: The Prehab Prescription- Evidence, Implementation, and Advocacy

exercise journal md identify define advocacy recognize implementation prescription interpret mhs prehab hosts dr thoracic surgery

Play Episode Listen Later Aug 21, 2025 22:24

What if we could train patients for surgery the way elite athletes train for game day? In this episode, we review the science, shed light on the disparities, explore real-world challenges, and honor the behind-the-scenes workers that facilitate prehabilitation in thoracic cancer care. Join attending surgeon Doctor Jinny Ha, 3rd year general surgery resident Doctor Kyla Rakoczy, and Community Outreach Patient Navigator, Leslie Ricks Chandler, in discussing prehabilitation in thoracic surgery. Hosts: Dr. Jinny Ha, MD, MHS, assistant professor of surgery and thoracic surgeon at Johns Hopkins Leslie Ricks Chandler, Community Outreach Program Advisor Johns Hopkins Thoracic Surgery Dr. Kyla Rakoczy, MD, 3rd year general surgery resident at Johns Hopkins LinkedIn: Kyla Rakoczy Learning objectives: After listening to this episode, participants will be able to: Define the role and components of prehabilitation in the context of thoracic oncology and ERAS/ESTS guidelines. Interpret key findings from recent clinical trials on prehabilitation, including outcomes related to functional capacity and readmission rates. Identify socioeconomic and structural barriers to prehabilitation participation and discuss strategies to improve equitable access to these interventions. Apply evidence-based criteria to assess which patients may benefit most from preoperative nutrition and exercise interventions. Recognize the importance of interdisciplinary collaboration—including social work and patient navigation—in optimizing surgical readiness and long-term outcomes. References: Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial - PubMed https://pmc.ncbi.nlm.nih.gov/articles/PMC12070588/ https://pubmed.ncbi.nlm.nih.gov/39775660/ https://ccts.amegroups.org/article/view/68030/html https://pubmed.ncbi.nlm.nih.gov/36435646/ https://www.sciencedirect.com/science/article/abs/pii/S1043067918301643?via%3Dihub https://pubmed.ncbi.nlm.nih.gov/30304509/ https://pubmed.ncbi.nlm.nih.gov/28385477/ https://pubmed.ncbi.nlm.nih.gov/27226400/ https://pubmed.ncbi.nlm.nih.gov/38546649/ https://pubmed.ncbi.nlm.nih.gov/38614212/ https://www.hopkinsmedicine.org/surgery/specialty-areas/thoracic-surgery/patient-education Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Optimizing NSCLC Care: Advances in Lung Biopsy and Biomarker Testing

Deep Breaths: Updates from CHEST

Play Episode Listen Later Aug 19, 2025

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Fabien Maldonado, MD, FCCP Guest: Adam H. Fox, MD, MSc Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role of pragmatic clinical research in refining biopsy approaches. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Maldonado is a Professor of Medicine and Thoracic Surgery, the Pierre Massion Director in Lung Cancer Research, and the Director of Interventional Pulmonology Research at Vanderbilt University; and Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

The Beat With Joel Dunning Ep. 117: Chest Tube Management

CTSNet To Go

Play Episode Listen Later Aug 7, 2025 42:07

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Mara Antonoff, Associate Professor of Thoracic and Cardiovascular Surgery and Program Director for Education at the University of Texas MD Anderson Cancer Center, and President of Women in Thoracic Surgery, about chest tubes. Chapters 00:00 Intro 02:21 JANS 1, Ross Long-Term Outcomes 04:12 JANS 2, Valve Replacement Pregnancy 07:09 JANS 3, Bronchopleural Fistula 09:36 JANS 4, AUTHEARTVISIT Study 11:51 Career Center 13:56 Video 1, Bicuspid AVR & AAR 16:15 Video 2, Cold Head-Warm Body Perfusion 19:00 Video 3, Dr. Kappetein Podcast 20:23 Dr. Antonoff Interview, Chest Tube Management 38:45 Closing They discuss single chest tube vs double chest tube, the benefits of single chest tubes, and various chest tube sizes. They also explore reducing chest drain pain, stitching the chest tube, and chest tube output thresholds for removal. Additionally, they cover drain removal, air leaks, and clamping. Joel also highlights recent JANS articles on whether the Ross procedure in young adults delivers favorable long-term clinical and QOL outcomes, a literature review including new data from the registry of pregnancy and cardiac disease III regarding valve replacement during pregnancy, a multi-institutional analysis of the treatment outcomes and prognostic factors in the ESSG-01 study, and the choice of surgical aortic valve replacement type and midterm outcomes in 50 to 65-year-olds. In addition, Joel explores bicuspid aortic valve repair and ascending aorta replacement, a guide to isolated cerebral perfusion using two bypass circuits, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Professor Pieter Kappetein about the future of revascularization. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned 1.) Ross Procedure in Young Adults Delivers Favorable Long-Term Clinical and QOL Outcomes 2.) Valve Replacement During Pregnancy: Literature Review Including New Data From the Registry of Pregnancy and Cardiac Disease III 3.) Bronchopleural Fistula: A Multi-Institutional Analysis of the Treatment Outcomes and Prognostic Factors in the ESSG-01 Study 4.) The Choice of Surgical Aortic Valve Replacement Type and Mid-Term Outcomes in 50 to 65-Year-Olds: Results of the AUTHEARTVISIT Study CTSNET Content Mentioned 1.) Bicuspid Aortic Valve Repair and Ascending Aorta Replacement  2.) Cold Head-Warm Body Perfusion: A Guide to Isolated Cerebral Perfusion Using Two Bypass Circuits 3.) The Atrium: The Future of Revascularization  Other Items Mentioned 1.) Guest Editor Series: Insights Into Pediatric Mechanical Circulatory Support 2.) Cardiac Surgical Arrest—An International Conversation Series 3.) Career Center 4.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

The Beat With Joel Dunning Ep. 116: Lifetime Management of Heart Valve Disease

CTSNet To Go

Play Episode Listen Later Aug 1, 2025 40:57

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Joseph Zacharias, a consultant cardiothoracic surgeon at the Lancashire Cardiac Center in Blackpool, England, about lifetime management of heart valve disease. Chapters 00:00 Intro 02:13 Early Intervention, Disease Management 04:40 JANS 1, Sept on Placental Support 07:04 JANS 2, Surgeon Well-Being 09:41 JANS 3, Cardiac 10:58 JANS 4, PPM in SAVR 12:57 JANS 5, Cardiac Registry 14:22 Video 1, Close U Ministernotomy 15:19 Video 2, Endo AVR & MVR 16:03 Video 3, VATS 17:20 Dr. Zacharias Interview, HVD 38:04 Upcoming Events 38:51 Closing They delve into Dr. Zacharias's recent paper titled “Lifetime Management of Heart Valve Disease—Treat It Early and Treat It Right, First Time,” and discuss how the idea for the paper originated highlighting key takeaways. They also address perceived risks vs actual risks and why less than 25 percent of patients are referred for necessary interventions. Additionally, they examine the future of cardiac surgery, endoscopic cardiac surgery, and endoscopic vein harvesting. Joel also highlights recent JANS articles on a novel and logistic approach for hypoplastic left heart syndrome with intact atrial septum, a European Society of Thoracic Surgery survey on member well-being, transcatheter management of left-sided valvular heart disease following heart transplantation, a multi-institutional study on the prevalence and clinical impact of patient-prosthesis mismatch in surgical aortic valve replacement, and a systematic review and meta-analysis of the German registry of acute aortic dissection type A score for 30-day mortality prediction in type A acute aortic dissection surgery. In addition, Joel explores how to close an upper ministernotomy, endoscopic aortic valve replacement and mitral valve replacement, and uniportal VATS decortication for late-stage TB empyema. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned 1.) Open Atrial Septectomy on Placental Support: A Novel and Logistic Approach for Hypoplastic Left Heart Syndrome With Intact Atrial Septum 2.) Fit2Perform: European Society of Thoracic Surgery Survey on Member Well-Being 3.) Transcatheter Management of Left-Sided Valvular Heart Disease Following Heart Transplantation 4.) A Multi-Institutional Study on the Prevalence and Clinical Impact of Patient-Prosthesis Mismatch in Surgical Aortic Valve Replacement 5.) The German Registry of Acute Aortic Dissection Type A Score for 30-Day Mortality Prediction in Type A Acute Aortic Dissection Surgery: A Systematic Review and Meta-Analysis CTSNet Content Mentioned 1.) How to Close an Upper Ministernotomy  2.) Endoscopic Aortic Valve Replacement and Mitral Valve Replacement  3.) Uniportal VATS Decortication for Late-Stage TB Empyema  Other Items Mentioned 1.) Lifetime Management of Heart Valve Disease—Treat It Early and Treat It Right, First Time 2.) Guest Editor Series Webinar: Coronary Arterial Anomalies—Pediatric and Adult Congenital 3.) Cardiac Surgical Arrest—An International Conversation, Part 4 4.) Career Center 5.) CTSNet Events Calendar

england video management german disease lifetime tb blackpool prevalence zacharias early intervention dunning jans european society ppm career center vats thoracic surgery heart valve

A Conversation with Dr. Lary Robinson

The Practice of Medicine

Play Episode Listen Later Aug 1, 2025 20:44

In this episode of the Southern Medicine Podcast, Loretta Loftus, MD, MBA, Vice Chair, Department of Breast Oncology at Moffitt Cancer Center, speaks with Lary Robinson, MD, a thoracic surgeon at Moffitt Cancer Center. Dr. Robinson reflects on his path to thoracic surgery, how the field has evolved, and key advances in lung cancer treatment—including the promise of immunotherapy and the importance of early screening. The conversation also touches on multidisciplinary care, as well as advice for primary care providers.

conversations mba md robinson vice chair oncology lung cancer lary moffitt cancer center thoracic surgery breast oncology

Breaking Barriers in Lung Cancer: Precision in Staging and Surgery

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Jun 26, 2025 47:10

In the third episode of our lung cancer miniseries, Jonathan Sackier is joined by Douglas E. Wood, Henry N. Harkins Professor and Chair of Surgery at the University of Washington. A global leader in thoracic oncology, Wood explores the critical role of lung cancer staging, the evolution of screening guidelines, and how surgical innovation is shaping the future of lung cancer treatment. Timestamps: 00:00 – Introduction 02:37 – Career beginnings 07:37 – Career highlights 11:38 – Thoracic oncology guidelines 15:26 – AI and big data 17:17 – Expanding lung cancer screening 19:29 – Robotic surgery 23:38 – Targeted therapies 27:23 – Cancer staging 30:44 – Lung volume reduction surgery 35:10 – Current trials 40:50 – Three wishes for healthcare

#10, S1 The 2024 Best Papers in Thoracic Surgery

papers thoracic surgery linda martin jeff yang uva health

Play Episode Listen Later Jun 11, 2025 47:42

What were the most practice-changing thoracic surgery papers of 2024? In this episode of Thinking Thoracic, Dr. Linda Martin, UVA Health, and Dr. Jeff Yang, Thinking Thoracic co-host, spotlight top studies shaping the field, from groundbreaking lung cancer and esophageal cancer findings to surgical profession papers that impact how surgeons work and lead. Dr. Martin's curated list is a go-to resource for surgeons looking to stay at the forefront of evidence-based care. Check out her GTSC Key Papers presentation here.

Lung Cancer Treatment

Anna Marie's Sunday Focus

Play Episode Listen Later Jun 11, 2025 29:36

Dr. John Lazar, Chief of Thoracic Surgery and Oncology at Ascension Saint Thomas in Nashville speaks about lung cancer, treatments, causes, and risk factors. The lung cancer rate is higher in Tennesee and other Southeastern states because the smoking rate is higher. He discusses an unexpected rise of lung cancers in women of a particular demographic with NO obvious risk factors who are, nevertheless, developing the cancers. He also tells Anna the latest developments in detecting lung cancers, both in blood testing and imaging.See omnystudio.com/listener for privacy information.

tennessee nashville chief treatments oncology southeastern thoracic surgery lung cancer treatment

Artificial Intelligence for the Clinician Ep. 3: Natural Language Processing and Large Language Models

Play Episode Listen Later Jun 2, 2025 45:28

Welcome back to our series on AI for the clinician! Large language models, like ChatGPT, have been taking the world by storm, and healthcare is no exception to that rule – your institution may already be using them! In this episode we'll tackle the fundamentals of how they work and their applications and limitations to keep you up to date on this fast-moving, exciting technology. Hosts: Ayman Ali, MD Ayman Ali is a Behind the Knife fellow and general surgery PGY-3 at Duke Hospital in his academic development time where he focuses on data science, artificial intelligence, and surgery. Ruchi Thanawala, MD: @Ruchi_TJ Ruchi Thanawala is an Assistant Professor of Informatics and Thoracic Surgery at Oregon Health and Science University (OHSU) and founder of Firefly, an AI-driven platform that is built for competency-based medical education. In addition, she directs the Surgical Data and Decision Sciences Lab for the Department of Surgery at OHSU. Phillip Jenkins, MD: @PhilJenkinsMD Phil Jenkins is a general surgery PGY-3 at Oregon Health and Science University and a National Library of Medicine Post-Doctoral fellow pursuing a master's in clinical informatics. Steven Bedrick, PhD: @stevenbedrick Steven Bedrick is a machine learning researcher and an Associate Professor in Oregon Health and Science University's Department of Medical Informatics and Clinical Epidemiology. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Journal Review in Artificial Intelligence: Applications of AI in Surgery

Play Episode Listen Later May 15, 2025 13:18

Welcome to our new series – the AI Journal Club! In this series, we'll cover some interesting studies and evidence-based applications of artificial intelligence in surgery in a case-based format. Surely AI can find a DVT by now … or can it? Stay tuned and find out! Hosts: - Ayman Ali, MD Ayman Ali is a Behind the Knife fellow and general surgery PGY-3 at Duke Hospital in his academic development time where he focuses on data science, artificial intelligence, and surgery. - Ruchi Thanawala, MD: @Ruchi_TJ Ruchi Thanawala is an Assistant Professor of Informatics and Thoracic Surgery at Oregon Health and Science University (OHSU) and founder of Firefly, an AI-driven platform that is built for competency-based medical education. In addition, she directs the Surgical Data and Decision Sciences Lab for the Department of Surgery at OHSU. - Marisa Sewell, MD: @MarisaSewell Marisa Sewell is a general surgery PGY-4 at Oregon Health and Science University. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

ai journal artificial intelligence assistant professor surgery applications knife firefly informatics oregon health science university dvt ohsu pgy thoracic surgery science university ohsu

Episode 12 : Part C - Evolution in cardiac surgery with Dr. Celmeta

Behind the OR

Play Episode Listen Later Apr 23, 2025 9:24

In this episode, Dr Bleri CELMETA takes us on a powerful journey through the history of open-heart surgery — from the pioneering work of John Gibbon and C. Walton Lillehei to the evolution of minimally invasive and robotic approaches. Discover how cardiac surgery progressed from experimental beginnings to life-saving daily procedures, and how innovation continues to shape the operating room. Dr. Bleri Celmeta is a cardiac surgeon operating on the Minimally Invasive Cardiac Surgery Unit in Galeazzi-Sant'Ambrogio Hospital (Milan, Italy). He graduated in Medicine and Surgery at the University of Padova-Italy in 2014, then completed his residency program in Cardiac Surgery in the same university in 2020. His professional background included also a fellowship in Cardiac and Thoracic Surgery in the University Hospital of Nantes-France (2019-2020).  He is the author of numerous publications and conference presentations with particular interest in minimally invasive cardiac surgery, and review editor of various international Journals (Frontiers in Cardiovascular Medicine, Frontiers in Surgery, Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, Journal of Cardiothoracic Surgery, among others). Dr. Celmeta is a member of the Working Group on Cardiovascular Surgery - European Society of Cardiology (ESC), Italian Cardiac Surgery Society (SICCH) and Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI). LinkedIn profile: Bleri Celmeta | LinkedIn About Behind the OR Behind the OR is the official podcast channel by Peters Surgical. Here, we invite you to step into the world of surgery, where we uncover what happens behind the closed doors of the operating room and beyond. Each episode features in-depth conversations with expert surgeons, providing insights into the latest surgical techniques, innovations, and the daily lives of those who dedicate themselves to saving lives. Founded in 1926, Peters Surgical is a French company with a global presence in over 90 countries. As a reference group for surgical practices worldwide, we are dedicated to improving surgical outcomes through innovative medical devices, including surgical sutures, hemostatic clips, and surgical glue. Our expertise lies in designing, manufacturing, and distributing these devices. Visit our website here : https://peters-surgical.com/

Journal Review in Thoracic Surgery: The ESOPEC Trial

Sterile Technique Podcast

Play Episode Listen Later Apr 17, 2025 24:58

Listen as we discuss the highly-awaited ESOPEC trial, which examines treatment regimens for esophageal and EGJ adenocarcinoma. Wildly impress your thoracic attendings or peers with your nuanced knowledge! FLOT who? You'll know. Pull out the paper and listen along! Learning Objectives: -Discuss the patient population in the ESOPEC trial -Discuss the main differences between the ESOPEC trial and the CROSS trial -Describe the main drawbacks between FLOT and the CROSS regimen. Hosts: Chloe Hanson MD, Brian Louie MD, and Peter White MD Referenced Material https://www.nejm.org/doi/full/10.1056/NEJMoa2409408 Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, Izbicki JR, Gockel I, Gerdes B, Ghadimi M, Reichert B, Lock JF, Bruns C, Reitsamer E, Schmeding M, Benedix F, Keck T, Folprecht G, Thuss-Patience P, Neumann UP, Pascher A, Imhof D, Daum S, Strieder T, Krautz C, Zimmermann S, Werner J, Mahlberg R, Illerhaus G, Grimminger P, Lordick F. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. N Engl J Med. 2025 Jan 23;392(4):323-335. doi: 10.1056/NEJMoa2409408. PMID: 39842010. https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. PMID: 22646630. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/abstract Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686. ***Fellowship Application Link: https://forms.gle/PQgAvGjHrYUqAqTJ9 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

cross trial journal lancet epub pmid piis0140 new england journal of medicine perioperative preoperative flot esophageal cancer thoracic surgery kaspers egj claus r

Robot-Assisted Thoracic Surgery in Non-Small Cell Lung Cancer

Play Episode Listen Later Apr 5, 2025 33:37

Welcome to the Sterile Technique Podcast! It's the podcast about Surgical Technology. Whether you are a CST or CSFA, this podcast helps you earn CE credits and improve your surgery skills in the OR. This episode discusses an article in the March 2025 issue of The Surgical Technologist, the official journal of the Association of Surgical Technologists (AST). The article is titled, "Robot-Assisted Thoracic Surgery in Non-Small Cell Lung Cancer". "Scrub in" at steriletpodcast.com and on Twitter, @SterileTPodcast (twitter.com/SterileTPodcast). This podcast is a Dybas Media production. Sound effects adapted from GarageBand and sindhu.tms at https://freesound.org/people/sindhu.tms/sounds/169065/ and licensed courtesy of https://creativecommons.org/licenses/by-nc/3.0/.

sound healthcare robots hospitals surgery surgical assisted garageband technologists scrub small cell lung cancer thoracic surgery non small cell lung cancer surgical technologist

Medical Monday 3/31/25: Thoracic Surgery with Dr. Byron Patton

Vox Pop

Play Episode Listen Later Mar 31, 2025 48:07

We welcome Dr. Byron Patton, Regional Chief of Thoracic Surgery at Nuvance Health. Sarah LaDuke hosts.

patton thoracic surgery nuvance health medical monday sarah laduke

Lung Cancer Considered in Hungarian

Compassion & Courage: Conversations in Healthcare

Play Episode Listen Later Mar 15, 2025 61:15

As part of IASLC's ongoing series of podcasts in world languages, Dr. Balazs Halmos moderates a discussion in Hungarian with Dr. Krisztina Bogos, Dr. Ferenc Rényi-Vámos and Dr. Zsolt Megyesfalvi. The podcast reviews recent advances in lung cancer screening, diagnosis and management with a particular focus on implementation in Hungary. Highlights of the discussion include novel staging and diagnostic tools, state-of-the-art biomarker testing, perioperative therapy and clinical trials access. Host: Balazs Halmos, MD, Director, Thoracic Oncology & Clinical Cancer Genomics, Montefiore Medical Park at Eastchester, Bronx, New York Guest: Ferenc Rényi-Vámos, MD, PhD, Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary Guest: Krisztina Bogos, MD, Thoracic Oncology National Koranyi Institute of Pulmonology, Budapest, Hungary Lung Cancer Research and Pathology Guest: Zsolt Megyesfalvi, MD, PhD, Semmelweis University and National Institute of Oncology, Budapest, Hungary and National Koranyi Institute of Pulmonology, Budapest, Hungary

director phd md bronx national institutes hungary budapest hungarian oncology lung cancer pulmonology thoracic surgery thoracic oncology semmelweis university

The Heart of Compassionate Care – Ryan Sheridan, Thoracic Surgery PA

Play Episode Listen Later Mar 10, 2025 34:19

In this episode of Compassion and Courage, Marcus speaks with Ryan Sheridan, a physician assistant specializing in cardiothoracic surgery. They discuss Ryan's journey into the medical field, the importance of compassionate communication in healthcare, and the flexibility of a PA's role. Ryan shares insights on how to practice compassion with patients, especially in post-operative care, and the significance of honesty when communicating both good and bad outcomes. Come listen to Ryan's experience with leadership skills, the importance of being present with patients, and personal stories that highlight the power of compassion in healthcare and just trying. Key Moments00:00 – Introductions00:45 – Ryan's Journey to Becoming a PA05:05 – Practicing Compassion in Post-Operative Care08:00 – Communicating Good and Bad Outcomes14:30 – The Impact of Compassion on Patient Care20:50 – Lessons in Leadership from Family23:50 – A Personal Story of Compassion29:40 – Getting to Know Ryan. "Enjoy It."34:15 – Conclusion and Thank Yous Resources for you: More communication tips and resources for how to cultivate compassion: https://marcusengel.com/freeresources/Connect with Marcus on LinkedIn: https://www.linkedin.com/in/marcusengel/Learn more about Marcus' Books: https://marcusengel.com/store/Subscribe to our podcast through Apple: https://bit.ly/MarcusEngelPodcastSubscribe to our podcast through YouTube: https://bit.ly/Youtube-MarcusEngelPodcast More about Ryan:Ryan Sheridan, Physician Assistant practicing Thoracic Surgery in New York. Date: 3/10/2025 Name of show: Compassion & Courage: Conversations in Healthcare Episode number and title: Episode 163 – The Heart of Compassionate Care – Ryan Sheridan, Thoracic Surgery PA

new york apple leadership lessons books heart courage impact compassion conclusion personal stories physician assistants compassionate care thoracic surgery ryan sheridan

Half a Heart

Innovation Now

Play Episode Listen Later Feb 28, 2025

A pediatric thoracic surgeon at Indiana University, has spent decades fixing broken hearts. And his research led him to a team of engineers at NASA.

technology innovation radio medicine jobs nasa indiana university prototype thoracic surgery fontan tech transfer circulatory pediatric medicine

Dr. Daniel Hale Williams

Stuff You Missed in History Class

Play Episode Listen Later Feb 12, 2025 43:19 Transcription Available

Dr. Daniel Hale Williams is often described as the first person to successfully perform an open-heart surgery. That's not entirely accurate, but he was still a surgical innovator, and he was also a huge part of the Black Hospital Movement. Research: "Daniel Hale Williams." Contemporary Black Biography, vol. 2, Gale, 1992. Gale In Context: U.S. History, link.gale.com/apps/doc/K1606000260/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=c4ae7664. Accessed 28 Jan. 2025. "Daniel Hale Williams." Notable Black American Men, Book II, edited by Jessie Carney Smith, Gale, 1998. Gale In Context: U.S. History, link.gale.com/apps/doc/K1622000479/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=80e75e7e. Accessed 28 Jan. 2025. Buckler, Helen. “Doctor Dan: Pioneer in American Surgery.” Little, Brown and Company. 1954. Cobb, W M. “Daniel Hale Williams-Pioneer and Innovator.” Journal of the National Medical Association vol. 36,5 (1944): 158-9. COBB, W M. “Dr. Daniel Hale Williams.” Journal of the National Medical Association vol. 45,5 (1953): 379-85. Cook County Health. “Celebrating 30 Years: Provident Hospital of Cook County.” https://cookcountyhealth.org/provident-hospital-30th-anniversary/ Gamble, Vanessa Northington. “Making a place for ourselves : the Black hospital movement, 1920-1945.” New York : Oxford University Press. 1995. Gamble, Vanessa Northington. “The Provident Hospital Project: An Experiment in Race Relations and Medical Education.” Bulletin of the History of Medicine, WINTER 1991. Via JSTOR. https://www.jstor.org/stable/44442639 Gordon, Ralph C. “Daniel Hale Williams: Pioneer Black Surgeon and Educator.” Journal of Investigative Surgery, 18:105–106, 2005. DOI: 10.1080/08941930590956084 Hughes, Langston. “Famous American Negroes.” Dodd Mead. 1954. Jackson State University. “Who Was Dr. Daniel Hale Williams?” https://www.jsums.edu/gtec/dr-daniel-hale-williams/ Jefferson, Alisha J. and Tamra S. McKenzie. “Daniel Hale Williams, MD: ‘A Moses in the profession.’” American College of Surgeons CC2017 Poster Competition. 2017. Office of the Illinois Secretary of State. “51. Dr. Daniel Hale Williams Letter to Governor Joseph Fifer (1889).” 100 Most Valuable Documents at the Illinois State Archives. https://www.ilsos.gov/departments/archives/online_exhibits/100_documents/1889-williams-letter-gov.html Olivier, Albert F. “In Proper Perspective: Daniel Hale Williams, M.D.” Annals of Thoracic Surgery. Volume 37, Issue 1p96-97 January 1984. https://www.annalsthoracicsurgery.org/article/S0003-4975(10)60721-7/fulltext Raman, Jai. “Access to the Heart – Evolution of surgical techniques.” Global Surgery. Vol. 1, No. 2. doi: 10.15761/GOS.1000112 Rock County, Wisconsin. “Dr. Daniel Hale Williams.” https://legacy.co.rock.wi.us/daniel-hale-williams Summerville, James. “Educating Black doctors : a history of Meharry Medical College.” University of Alabama Press. https://archive.org/details/educatingblackdo0000summ/ The Provident Foundation. “History- Dr. Daniel Hale Williams.” https://provfound.org/index.php/history/history-dr-daniel-hale-williams “Early Chicago: Hospital of Hope.” DuSable to Obama: Chicago’s Black Metropolis. https://www.wttw.com/dusable-to-obama/provident-hospital See omnystudio.com/listener for privacy information.

IASLC Lung Cancer Considered in German

Play Episode Listen Later Jan 22, 2025 52:45

Description: As part of IASLC's commitment to communicating in all world languages, this episode of Lung Cancer Considered is recorded in German and is part of our Virtual Tumor Board series. Host Professor Alessandra Curioni-Fontecedro moderates a discussion with two colleagues, who will discuss the dynamic topic of managing resectable stage III NSCLC. Host: Prof Alessandra Curioni-Fontecedro, MD, Head of Oncology, Cantonal Hospital Fribourg, Chair of Medical Oncology, University of Fribourg Guest: Prof. Isabelle Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the past President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surgery at the 2022 World Conference on Lung Cancer Guest: Prof. Michael Thomas, Chefarzt of Dept of Thoracic Oncology at the Thoraxklinik Heidelberg, Germany.

#4, S1 Management of Emergencies in Thoracic Surgery

management emergencies cleveland clinic thoracic surgery

Play Episode Listen Later Jan 7, 2025 47:12

In this episode, Dr. Hari Keshava talks with Dr. Sid Murthy, section head, thoracic surgery at Cleveland Clinic, about thoracic surgical emergencies related to pulmonary and lung surgeries...and how optimal management of these situations often requires surgeons to anticipate, collaborate and be prepared with a well-thought-out action plan.

Clinical Challenges in Thoracic Surgery: Management of Bronchopleural Fistula after Pneumonectomy

Play Episode Listen Later Dec 16, 2024 37:44

Your post op day #4 right pneumonectomy patient is suddenly coughing up large volumes of serosanguinous sputum! What are you worried about and what do you need to do? Join your Swedish thoracic surgery team, Drs. Chloe Hanson, Peter White, and Brian Louie as we discuss the management of this dangerous and frustrating surgical complication. Hosts: Chloe E. Hanson, M.D., PGY3 Brian E. Louie, MD, Thoracic Attending Peter T. White, MD, Thoracic Attending Learning Objectives: What is a bronchopleural fistula (BPF) and what different ways do they present? Describe the acute management of an early BPF. Describe the differences in operative considerations between an early and late BPF. Describe different options for closure of a pneumonectomy space. References: - Sugarbaker's Adult Chest Surgery, 3e Sugarbaker DJ, Bueno R, Burt BM, Groth SS, Loor G, Wolf AS, Williams M, Adams A. Sugarbaker D.J., & Bueno R, & Burt B.M., & Groth S.S., & Loor G, & Wolf A.S., & Williams M, & Adams A(Eds.),Eds. David J. Sugarbaker, et al. https://shc.amegroups.org/article/view/3787/html - Dal Agnol G, Vieira A, Oliveira R, Ugalde Figueroa PA. Surgical approaches for bronchopleural fistula. Shanghai Chest 2017;1:14. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

challenges management md swedish clinical references drs surgical eds peter white fistula thoracic surgery bpf pneumonectomy

Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System

Chicago's Afternoon News with Steve Bertrand

Play Episode Listen Later Nov 29, 2024 35:45

In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests preview the publication of the Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System for lung cancer. The new edition will be published in January 2025 and has some important changes that reflect an evolving understanding of the disease and more rigorous analysis of data from around the world. Guest: Dr. Valerie Rusch is a Thoracic Surgeon from Memorial Sloan Kettering Cancer CenterMSKCC where she is Vice Chair for Clinical Research in the Department of Surgery and the Miner Family Chair in Intrathoracic Cancers. She has held many leadership positions in the American College of Surgeons and other organizations and was part of the team to first described EGFR mutations. She has been chair of the Thoracic Committee for the American Joint Committee on Cancer 6th, 7th, 8th, and now 9th Editions of the Cancer Staging Handbook Guest: Dr. Hisao Asamura is a Professor of Surgery, Chief of Division of Thoracic Surgery at Keio University School of Medicine in Tokyo, Japan and Vice President of the Japan Lung Cancer Society. For IASLC, he is the Chair of the Staging and Prognostic Factors Committee, former Executive Board Director, and Congress President for the 18th World Conference on Lung Cancer. Guest: Dr. Enrico Ruffini is a Thoracic Surgeon and Professor of Thoracic Surgery from the University of Torino, Italy where he is the Chief of the Thoracic Surgery Unit and Director of the Thoracic Surgery Residency Program. He is heavily involved in the European Society of Thoracic Surgeons and Chair of the IASLC Staging and Prognostic Factors Committee – Thymic domain.

Is there a connection between COVID-19 and cancer regression?

Play Episode Listen Later Nov 22, 2024

Dr. Ankit Bharat, Chief of Thoracic Surgery and Director of the Canning Thoracic Institute at Northwestern Medicine, joins Lisa Dent on the show to share details surrounding a study that shows there is a connection between COVID-19 and cancer regression.

Episode 8 : Part B - Evolution in cardiac surgery with Dr. Celmeta

Behind the OR

Play Episode Listen Later Nov 15, 2024 8:07

Many significant medical discoveries were accidents, such as Fleming's discovery of penicillin in 1929. Similarly, in 1958, Dr. Mason Sones from the Cleveland Clinic accidentally injected contrast into a patient's right coronary artery, leading to a cardiac arrest. However, this incident allowed the first detailed visualization of the coronary artery, eventually leading to the development of coronary angiography, which remains the gold standard today. Dr Bleri CELMETA highlight these advancements, and explains the evolutions from open procedures to minimally invasive and robotic techniques. Dr. Bleri Celmeta is a cardiac surgeon operating on the Minimally Invasive Cardiac Surgery Unit in Galeazzi-Sant'Ambrogio Hospital (Milan, Italy). He graduated in Medicine and Surgery at the University of Padova-Italy in 2014, then completed his residency program in Cardiac Surgery in the same university in 2020. His professional background included also a fellowship in Cardiac and Thoracic Surgery in the University Hospital of Nantes-France (2019-2020).  He is the author of numerous publications and conference presentations with particular interest in minimally invasive cardiac surgery, and review editor of various international Journals (Frontiers in Cardiovascular Medicine, Frontiers in Surgery, Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, Journal of Cardiothoracic Surgery, among others). Dr. Celmeta is a member of the Working Group on Cardiovascular Surgery - European Society of Cardiology (ESC), Italian Cardiac Surgery Society (SICCH) and Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI). LinkedIn profile: Bleri Celmeta | LinkedIn About Behind the OR Behind the OR is the official podcast channel by Peters Surgical. Here, we invite you to step into the world of surgery, where we uncover what happens behind the closed doors of the operating room and beyond. Each episode features in-depth conversations with expert surgeons, providing insights into the latest surgical techniques, innovations, and the daily lives of those who dedicate themselves to saving lives. Founded in 1926, Peters Surgical is a French company with a global presence in over 90 countries. As a reference group for surgical practices worldwide, we are dedicated to improving surgical outcomes through innovative medical devices, including surgical sutures, hemostatic clips, and surgical glue. Our expertise lies in designing, manufacturing, and distributing these devices. Visit our website here : https://peters-surgical.com/

November is Lung Cancer Awareness Month: What to Know

MedStar Health DocTalk

Play Episode Listen Later Nov 4, 2024 24:11

Send us a textLung cancer is the leading cause of cancer deaths in both men and women, resulting in more cancer deaths than breast, prostate, and colorectal cancers combined. It can take years to develop and is difficult to detect in early stages when there is greater potential for a cure. Fortunately, lung cancer survival rates are improving, thanks to advances in screening and treatment options, including breakthrough therapies that we're leading at MedStar Health. In partnership with the Georgetown Lombardi Comprehensive Cancer Center—a National Cancer Institute-designated comprehensive cancer center—we can offer our patients promising clinical trials years before they become the standard of care. Dr. Edward Chan is the Chief of Thoracic Surgery at MedStar Washington Hospital Center. Dr. Chan sees patients at MedStar Washington Hospital Center and MedStar Georgetown University Hospital. Dr. Chan is double-board certified and specializes in general thoracic surgery. He treats patients for lung cancer, esophageal cancer, benign esophageal diseases (such as acid reflux/hiatal hernia and achalasia), and mediastinal tumors. For an interview with Dr. Edward Chan, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net. Learn more about Dr. Chan. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

chief chan lung cancer national cancer institute thoracic surgery lung cancer awareness month medstar health medstar washington hospital center medstar georgetown university hospital

IASLC - Hot Topic Meeting On Tolerance And Resistance To Targeted Therapy In NSCLC 2

The ABMP Podcast | Speaking With the Massage & Bodywork Profession

Play Episode Listen Later Oct 29, 2024 23:06

Title: IASLC Hot Topic Meeting on Tolerance and Resistance to Targeted Therapy in NSCLC (recorded on 10/21) Description: In this episode of Lung Cancer Considered, host Dr. Stephen Liu previews the upcoming IASLC Hot Topic Meeting on Tolerance and Resistance to Targeted Therapy in NSCLC. To discuss this exciting new meeting and this topic, he is joined by the four co-chairs of the meeting. To learn more about the meeting, visit https://www.httr2024-iaslc.org/. Guest: Dr. Alice Berger is an Associate Professor in the Human Biology Division and the Herbold Computational Biology Program at the Fred Hutchinson Cancer Center at the University of Washington in Seattle, Wash. X: @aliceb_phd Guest: Dr. Kenichi Suda, Associate Professor in the Division of Thoracic Surgery at Kindai University School of Medicine in Osaka, Japan. X: NA Guest: Dr. Montse Sanchez-Cespedes is the Group Leader at the Josep Carreras Research Institute, in Badalona, Spain X: @CespedesMontse Guest: Dr. William Lockwood, Senior Scientist in Integrative Oncology at the BC Cancer Research Institute and Associate Professor in Pathology & Laboratory Medicine at the University of British Columbia in Vancouver, Canada X: @WWL_18

Ep 465 – TAVR Surgery: “I Have a Client Who . . .” Pathology Conversations with Ruth Werner

Play Episode Listen Later Oct 8, 2024 20:54

A client had a complex surgical procedure on her heart two weeks prior, but it was conducted by way of a catheter threaded up her femoral artery and aorta. Now, she wants to receive massage again. A quick Google search suggests that it would be OK. Her MT is skeptical and wants to be more conservative. Who is right? Listen on for information about transcatheter aortic valve replacement (TAVR) surgery, using AI to make clinical decisions, and how to get to “yes” for people who have recently had surgery. Host Bio:                   Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.                   Resources:  Pocket Pathology: https://www.abmp.com/abmp-pocket-pathology-app Braun, L.A. et al. (2012) ‘Massage therapy for cardiac surgery patients--a randomized trial', The Journal of Thoracic and Cardiovascular Surgery, 144(6), pp. 1453–1459, 1459.e1. Available at: https://doi.org/10.1016/j.jtcvs.2012.04.027. Grafton-Clarke, C. et al. (2019) ‘Can postoperative massage therapy reduce pain and anxiety in cardiac surgery patients?', Interactive Cardiovascular and Thoracic Surgery, 28(5), pp. 716–721. Available at: https://doi.org/10.1093/icvts/ivy310. Patients Who Stay in Hospital Less Than 3 Days After TAVR Fare Better (no date) American College of Cardiology. Available at: https://www.acc.org/about-acc/press-releases/2019/03/04/13/53/http%3a%2f%2fwww.acc.org%2fabout-acc%2fpress-releases%2f2019%2f03%2f04%2f13%2f53%2fpatients-who-stay-in-hospital-less-than-3-days-after-tavr-fare-better (Accessed: 26 September 2024). Pressler, A. et al. (2018) ‘Long-term effect of exercise training in patients after transcatheter aortic valve implantation: Follow-up of the SPORT:TAVI randomised pilot study', European Journal of Preventive Cardiology, 25(8), pp. 794–801. Available at: https://doi.org/10.1177/2047487318765233. Transcatheter Aortic Valve Replacement (TAVR) (no date). Available at: https://my.clevelandclinic.org/health/treatments/17570-transcatheter-aortic-valve-replacement-tavr (Accessed: 25 September 2024). Wang, A.T. et al. (2010) ‘Massage therapy after cardiac surgery', Seminars in Thoracic and Cardiovascular Surgery, 22(3), pp. 225–229. Available at: https://doi.org/10.1053/j.semtcvs.2010.10.005. What recovery looks like 6 months after an aortic valve replacement (2023). Available at: https://www.medicalnewstoday.com/articles/6-months-after-aortic-valve-replacements (Accessed: 25 September 2024). Sponsors: Anatomy Trains: www.anatomytrains.com  Elements Massage: www.elementsmassage.com/abmp MassageBook: www.massagebook.com Books of Discovery: www.booksofdiscovery.com The American Massage Conference: www.massagetherapymedia.com/conferences

S11 Ep20: FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC

OncLive® On Air

Play Episode Listen Later Oct 3, 2024 15:09

In today's episode, supported by AstraZeneca, we had the pleasure of speaking with Sandip P. Patel, MD, and Brendon M. Stiles, MD, about the FDA approval of perioperative durvalumab (Imfinzi) for patients with resectable non–small cell lung cancer (NSCLC). Dr Patel is a professor of medicine in the Department of Medicine at the University of California, San Diego. Dr Stiles is a professor of cardiothoracic surgery and chief of the Divisions of Thoracic Surgery and Surgical Oncology in the Department of Cardiothoracic & Vascular Surgery, as well as the associate director of Surgical Oncology at the Montefiore Einstein Comprehensive Cancer Center in Bronx, New York. On August 15, 2024, the FDA approved durvalumab plus platinum-containing chemotherapy in the neoadjuvant setting, followed by durvalumab monotherapy in the adjuvant setting, for the treatment of adult patients with resectable NSCLC with no known EGFR mutations or ALK rearrangements. This regulatory decision was backed by findings from the phase 3 AEGEAN trial (NCT03800134), in which the median event-free survival was not reached (95% CI, 31.9 months-not estimable [NE]) in patients who received the durvalumab regimen vs 25.9 months (95% CI, 18.9-NE) in those who received placebo plus chemotherapy (stratified HR, 0.68; 95% CI, 0.53-0.88; P = .0039). In our exclusive interview, Drs Patel and Stiles discussed the significance of this approval, key efficacy and safety findings from AEGEAN, and how the clinical use of perioperative treatment regimens reinforces the importance of involving multidisciplinary teams in every step of a patient's treatment plan.

#721 - Dennis Modry

Shaun Newman Podcast

Play Episode Listen Later Oct 3, 2024 107:53

Dennis received his B.Sc. and M. D. Degrees from the University of Alberta, and his MSc. Degree and training in General Surgery, Cardiovascular and Thoracic Surgery and Critical Care at McGill University, he spent 3 more years of training in transplantation immunology, heart and lung transplantation and high-risk cardiovascular surgery at Stanford University Medical Center. He implemented Western Canada's first heart and lung transplantation program and served as the Director of both the Heart and Lung Transplantation Program and Cardiovascular Intensive Care Unit for 20+ years. He spent 30 years as a practising doctor and is the former CEO of the Alberta Prosperity Project. We discuss Alberta's position in Canada, the pace of government and the Alberta first mindset. Clothing Link:⁠⁠⁠https://snp-8.creator-spring.com/listing/the-mashup-collection⁠⁠ Text Shaun 587-217-8500 Substack:https://open.substack.com/pub/shaunnewmanpodcast E-transfer here: shaunnewmanpodcast@gmail.com Silver Gold Bull Links: Website: https://silvergoldbull.ca/ Email: SNP@silvergoldbull.com Text Grahame: (587) 441-9100

ceo director university canada heart degree degrees msc mcgill university cardiovascular western canada critical care general surgery stanford university medical center thoracic surgery

IASLC LALCA Preview (in Spanish)

director science education research spanish colombia associate professor surgery fundaci bogot thoracic surgery

Play Episode Listen Later Sep 25, 2024 46:10

Host Dr. Narjust Florez previews the 2024 Latin America Lung Cancer Meeting with co-chairs Dr. Lucia Viola, Dr. Andres Feliple Cardona and Dr. Stella Martinez. LALCA is a dynamic meeting with a long tradition that features the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. Guest: Dr. Lucia Viola Interventional Pulmonologist- Head of Thoracic Oncology Service. She is a member of the Fundación Neumológica Colombiana - Fundación CTICGuest: Dr. Andrés Felipe Cardona is the Director of Research, Science and Education of the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) located in Bogotá, Colombia. Guest: Dr. Stella Martinez is an Associate Professor of thoracic Surgery and Director of the Specialization Program in Thoracic Surgery at El Bosque University in Bogotá, Colombia.

Lessons from the Frontlines: Medical Leaders Tackle Healthcare Challenges

Business RadioX ® Network

Play Episode Listen Later Aug 26, 2024

In this episode of High Velocity Careers, Stone Payton speaks with Dr. Daniel Fortes, Division Chief of Thoracic Surgery at Wellstar, and Will Chilvers, the Director of Outpatient Imaging Services at Northside Hospital. They discuss their unique career paths, the challenges they face in healthcare, and the importance of combining clinical expertise with business acumen. […]

director lessons challenges leaders healthcare medical tackle front lines division chief thoracic surgery northside hospital wellstar health system stone payton

What Every Woman Needs to Know About Lung Cancer

The Great Girlfriends Show

Play Episode Listen Later Aug 23, 2024 36:00

Did you know that...- 1 IN 16 PEOPLE will be diagnosed with lung cancer in their lifetime- LUNG CANCER kills almost 3 times as many women as breast cancer- Approximately 127,070 AMERICAN LIVES are lost annually to lung cancer.And there's much more to be learned about lung cancer and how it's affecting women.This week Sybil is joined by Dr. Loretta Erhunmwunsee to discuss everything we need to know to protect ourselves from lung cancer + the environmental impacts that increase the rates of lung cancer diagnosis in black and brown communities more than others.Listen and learn:Who is most at risk for lung cancerWho should get screened for lung cancer and whyNon-smokers: how do you protect yourself from lung cancer?How insurance coverage affects screenings and treatmentsAND MORE!Special thanks to HealthyWomen in partnership with Daiichi Sankyo and Merck for introducing this topic to our audience.

IASLC - WCLC 2024 Preview

university professor medicine chief associate professor surgery moraes lung cancer california san diego radiation oncology world conference thoracic surgery linda martin wclc

Play Episode Listen Later Aug 13, 2024 42:25

Description: In this episode of Lung Cancer Considered, host (and WCLC 2024 Co-Chair) Dr. Narjust Florez previews the upcoming IASLC 2024 World Conference on Lung Cancer with the meeting's other three co-chairs. Guest: Dr. Linda Martin, Professor of Surgery and Chief of Thoracic Surgery at the University of Virginia. Guest: Dr. Fabio Ynoe de Moraes, Chief of Global Radiation Oncology and Associate Professor of Radiation Oncology at Queen University. Guest: Dr. Sandip Patel, Professor of Medicine and Thoracic Medical Oncologist at the University of California San Diego.

EP 117: Transforming Cardiac Surgery Recovery: Evidence-Based Insights with Dr Gerdisch

Parallax by Ankur Kalra

Play Episode Listen Later Aug 12, 2024 40:47

This week on Parallax, Dr Ankur Kalra welcomes Dr Marc Gerdisch to discuss a groundbreaking study on reducing opioid use after cardiac surgery. Dr Marc Gerdisch is the Chief of Cardiovascular and Thoracic Surgery and Co-Director of the Heart Valve Center and Atrial Fibrillation Program at Franciscan St. Francis Health. He is a senior partner at Cardiac Surgery Associates and a Clinical Assistant Professor of Thoracic and Cardiovascular Surgery at Loyola University Medical Center in Chicago. Dr Gerdisch shares insights into his research on rigid sternal fixation and enhanced recovery protocols, which have shown promising results in postoperative pain management and patient recovery. In this episode, Dr Kalra and Dr Gerdisch discuss the specifics of the study, including the four-cohort design and the steps taken to expedite opioid-free recovery. Dr Gerdisch also shares valuable advice on overcoming physician inertia and building a strong case for implementing such a programme, including cost-benefit analysis considerations. What motivated the study? How can a holistic approach to cardiac surgery recovery be implemented? What advice does Dr Gerdisch have for our listeners? Sources: Gerdisch MW, et al. Ann Thorax Surg 2024. Rigid Sternal Fixation and Enhanced Recovery for Opioid-Free Analgesia After Cardiac Surgery. DOI: 10.1016/j.athoracsur.2024.06.032 CE Cox. TCTMD 2024. Holistic Approach to Cardiac Surgery Can Sharply Cut Opioid Use. Available at: https://www.tctmd.com/news/holistic-approach-cardiac-surgery-can-sharply-cut-opioid-use. Accessed August 12, 2024.

chicago recovery chief transforming co director holistic approach cardiovascular evidence based doi clinical assistant professor parallax thoracic cardiac surgery thoracic surgery enhanced recovery accessed august loyola university medical center cardiovascular surgery

Bridging Communities: The UK Markey Cancer Center Affiliate Network

Talking FACS

Play Episode Listen Later Aug 8, 2024 14:55 Transcription Available

Host: Dr. Jennifer Hunter, Assistant Director for Family and Consumer Sciences Extension, University of Kentucky Guests: Dr. Timothy Mullett, Medical Director and Professor of Thoracic Surgery and Ms. Cheri Tolle, Deputy Director, UK Markey Cancer Center Affiliate Network (MCCAN) In this episode, we delve into the origins and growth of the UK Markey Cancer Center Affiliate Network (MCCAN), since its inception in 2006 with just three hospitals, MCCAN has expanded to include 19 hospitals across Kentucky. Discover how this network fosters high-quality cancer care, allowing patients to receive top-notch treatment close to home, and when necessary, facilitating seamless referrals to the Markey Cancer Center in Lexington. Explore the compelling reasons why the National Cancer Institute designation is a game-changer for the Markey Cancer Center and its affiliates, with insights into the comprehensive support offered to community hospitals, including professional education, quality assurance, and patient navigation services. This episode underscores the importance of collaboration between community hospitals and the Markey Cancer Center, ensuring that patients benefit from advanced research and specialized care. MCCAN is transforming cancer care in Kentucky, making a profound impact on patients and communities alike by bringing cutting-edge cancer care to many far-reaching spaces across Kentucky. Cancer Conversations on Talking FACS is a partnership project between Family and Consumer Sciences Extension and the Markey Cancer Center. For more information about MCCAN visit: Markey Cancer Center Affiliate Network Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On Twitter @UKMarkey Connect with FCS Extension through any of the links below: Kentucky Extension Offices UK FCS Extension Website Facebook Instagram FCS Learning Channel

family university discover professor ms explore network kentucky communities bridging deputy director assistant directors medical director lexington affiliate national cancer institute markey cancer centers thoracic surgery mccan jennifer hunter

Journal Review in Thoracic Surgery: Health Consequences of Thymectomy in Adults

health risk journal md consequences adults nejm new england journal of medicine thoracic surgery

Play Episode Listen Later Jul 25, 2024 25:32

Does the adult thymus have a purpose and function? Are there any long-term health effects of thymectomy? Tune in to another Swedish Thoracic surgery journal review where we discuss the recent paper out of the NEJM which reports on the health consequences of thymus removal in adults. This paper has been widely picked up by the media and our patients frequently bring it into the office. Listen as we discuss the study population, methods, and potential applications of this paper. Learning Objectives: - Review the purpose and function of the thymus. - Discuss the population, methods, and results of this trial. - Discuss the application of this paper and how it may or may not impact clinical practice for thoracic surgeons. Hosts: Chloe E. Hanson, MD, PGY-3 Kelly Daus MD, PGY-4 Peter White, MD, Thoracic Surgery Attending Brian Louie, MD, Thoracic Surgery Attending Reference Material: Kooshesh KA, Foy BH, Sykes DB, Gustafsson K, Scadden DT. Health Consequences of Thymus Removal in Adults. N Engl J Med. 2023;389(5):406-417. https://pubmed.ncbi.nlm.nih.gov/37530823/ Lin TM, Chang YS, Hou TY, et al. Risk of incident autoimmune diseases in patients with thymectomy. Ann Clin Transl Neurol. 2020;7(7):1072-1082. https://pubmed.ncbi.nlm.nih.gov/32478484/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Evolution in Cardiac Surgery

Behind the OR

Play Episode Listen Later Jul 16, 2024 9:34

In this podcast, Dr Bleri CELMETA explore the history and evolution of cardiac surgery. The series covers early challenges, such as : The belief that Heart Surgery was impossible and fatal The invention of the heart-lung machine Significant milestones like Alexis Carrel's vascular techniques and the first successful heart surgery in 1896 The podcast highlights the advancements that made modern cardiac surgery possible, emphasizing the evolution of medical practices and technologies. Dr. Bleri Celmeta is a cardiac surgeon operating on the Minimally Invasive Cardiac Surgery Unit in Galeazzi-Sant'Ambrogio Hospital (Milan, Italy). He graduated in Medicine and Surgery at the University of Padova-Italy in 2014, then completed his residency program in Cardiac Surgery in the same university in 2020. His professional background included also a fellowship in Cardiac and Thoracic Surgery in the University Hospital of Nantes-France (2019-2020).  He is the author of numerous publications and conference presentations with particular interest in minimally invasive cardiac surgery, and review editor of various international Journals (Frontiers in Cardiovascular Medicine, Frontiers in Surgery, Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, Journal of Cardiothoracic Surgery, among others). Dr. Celmeta is a member of the Working Group on Cardiovascular Surgery - European Society of Cardiology (ESC), Italian Cardiac Surgery Society (SICCH) and Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI). LinkedIn profile: Bleri Celmeta | LinkedIn About Behind the OR Behind the OR is the official podcast channel by Peters Surgical. Here, we invite you to step into the world of surgery, where we uncover what happens behind the closed doors of the operating room and beyond. Each episode features in-depth conversations with expert surgeons, providing insights into the latest surgical techniques, innovations, and the daily lives of those who dedicate themselves to saving lives. Founded in 1926, Peters Surgical is a French company with a global presence in over 90 countries. As a reference group for surgical practices worldwide, we are dedicated to improving surgical outcomes through innovative medical devices, including surgical sutures, hemostatic clips, and surgical glue. Our expertise lies in designing, manufacturing, and distributing these devices. Visit our website here : https://peters-surgical.com/

#158; S4: Same Surgeon, Different Light w/ Dr. Isabelle Opitz

Play Episode Listen Later Jul 8, 2024 30:41

Isabelle Opitz, MD, is the director of the Department of Thoracic Surgery at University Hospital Zurich, Switzerland, and an associate professor for thoracic surgery at the University of Zurich, as well as the chair of the Lung Cancer Center in Zurich. In this episode of Same Surgeon, Different Light, Dr. Opitz talks with Dr. Thomas Varghese about her international career path, spanning Germany, France, and Switzerland, where she now resides. She explains how career journeys in Europe differ from the US, especially for women, and how the healthcare system overseas is striving for greater diversity and inclusion in the workplace.

university europe france germany md switzerland surgeons zurich thoracic surgery different light opitz university hospital zurich

#157; S4: Same Surgeon, Different Light w/ Dr. Yolonda Colson

surgeons harvard medical school olson massachusetts general hospital thoracic surgery different light yolonda

Play Episode Listen Later Jun 26, 2024 49:09

In this episode, Dr. Thomas Varghese joins Dr. Yolonda Colson, chief of the Division of Thoracic Surgery at Massachusetts General Hospital and professor of surgery at Harvard Medical School, in an insightful conversation on the advancement of women into key leadership roles and why that is still lacking today in the cardiothoracic surgery specialty. Dr. Olson shares her origin story - "from farm to the CT surgery field" - as an accomplished surgeon and scientist. Her advice on becoming a consistently high performer? "Stay focused on your purpose and not just the result. And stay open to new opportunities."

Guyana, America, & Thoracic Surgery.

Linchpin Conversations

Play Episode Listen Later Jun 14, 2024 40:47

Melanie is a single mom with 2 kids & a Linchpin member. She was born & raised in Guyana & moved to the US when she was 11 years old. She has an amazing career as a Thoracic Surgery PA & stays very busy raising her 2 kids & getting them to their sports practices/games. This is her story.

america guyana linchpin thoracic surgery

The Silent Threat of Esophageal Cancer

MedStar Health DocTalk

Play Episode Listen Later May 15, 2024 34:04 Transcription Available

Comprehensive, relevant and insightful conversations about health and medicine from the largest healthcare system in the Maryland D.C. region: this is MedStar Health DocTalk.In our latest podcast episode, host Debra Schindler talks with thoracic surgeon Dr. Duane Monteith and gastroenterologist Dr. Dana Sloan for a comprehensive look into esophageal cancer. They discuss everything from early symptoms and risk factors to advanced treatment options like minimally invasive surgery. This episode is packed with valuable insights that could make a significant difference in early detection and treatment. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

threats silent comprehensive chemotherapy gastroenterology endoscopy radiation therapy dysphagia esophageal cancer thoracic surgery minimally invasive surgery squamous cell carcinoma adenocarcinoma medstar health

Clinical Challenges in Thoracic Surgery: Malignant Pleural Mesothelioma

The Skeptics Guide to Emergency Medicine

Play Episode Listen Later Apr 18, 2024 37:34

In this episode our team dives into the diagnosis, workup and management of malignant pleural mesothelioma. Listen as we debate the pros and cons of surgical management of this disease with extrapleural pneumonectomy versus pleural decortication and discuss the nuances of choosing the right approach for the right patient. Learning Objectives - Describe the workup and staging of a patient with malignant pleural mesothelioma - List the subtypes of malignant pleural mesothelioma, characteristics of resectable disease, and patient factors which impact surgical candidacy - Describe the approach to an extrapleural pneumonectomy and pleural decortication - Analyze which surgical approach is best for various subsets of patients - Describe the adjuvant treatment for malignant pleural mesothelioma Hosts Kelly Daus MD, Adam Bograd MD, Peter White MD, Brian Louie MD Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out more recent episodes: https://app.behindtheknife.org/listen

challenges clinical analyze malignant mesothelioma pleural thoracic surgery learning objectives describe

SGEM#433: Breathe – Simple Aspiration vs. Drainage for Complete Pneumothorax

Play Episode Listen Later Mar 23, 2024 37:57

Reference: Marx et al. Simple Aspiration versus Drainage for Complete Pneumothorax: A Randomized Noninferiority Trial. Am J Respir Crit Care Med. 2023 Date: March 22, 2024 Guest Skeptic: Dr. Richard Malthaner holds the prestigious position of Chair/Head of the Division of Thoracic Surgery and serves as the Director of the Thoracic Robotic Program at Western […] The post SGEM#433: Breathe – Simple Aspiration vs. Drainage for Complete Pneumothorax first appeared on The Skeptics Guide to Emergency Medicine.

director simple western breathe aspirations emergency medicine drainage pneumothorax skeptics guide thoracic surgery sgem

Journal Review in Thoracic Surgery: Lobar vs Sublobar Resection for Stage 1A NSCLC – CALGB & JCOG

Play Episode Listen Later Dec 7, 2023 48:10

In this episode our team reviews the two groundbreaking RCTs which challenged the long-held dogma that a lobectomy is the only acceptable oncologic procedure for NSCLC. Listen as we compare and contrast the North American CALGB trial and Japanese JCOG trial which were both designed to investigate survival and recurrence outcomes by randomizing stage 1A patients to lobectomy versus a sublobar resection. Learning Objectives: -Compare and contrast the patient characteristics of the CALGB and JCOG trials -Understand the methodology each trial and be able to explain their nuanced differences -Analyze the results of the CALGB and JCOG trials and how they apply to patients today Hosts: Kelly Daus MD, Peter White MD, Eric Vallieres, MD and Brian Louie MD Referenced Material https://pubmed.ncbi.nlm.nih.gov/36780674/ Altorki N, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Feb 9;388(6):489-498. doi: 10.1056/NEJMoa2212083. PMID: 36780674; PMCID: PMC10036605. https://pubmed.ncbi.nlm.nih.gov/35461558/' Saji H, et al. West Japan Oncology Group and Japan Clinical Oncology Group. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3. PMID: 35461558. https://pubmed.ncbi.nlm.nih.gov/37473998/ Altorki N, et al. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). J Thorac Cardiovasc Surg. 2023 Jul 18:S0022-5223(23)00612-8. doi: 10.1016/j.jtcvs.2023.07.008. Epub ahead of print. PMID: 37473998. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our other Cardiothoracic episodes: https://behindtheknife.org/podcast-category/cardiothoracic/

journal stage md alliance analyze lancet epub 1a pmid rcts new england journal of medicine nsclc thoracic surgery resection cardiothoracic calgb lobectomy segmentectomy

Clinical Challenges in Thoracic Surgery: Complex Pleural Effusions & Empyema - Part 2 of 2

Play Episode Listen Later Aug 17, 2023 22:33

In this two-part episode our team debates management of complex pleural effusions and empyema. Our surgical team is joined by Dr. Jed Gorden, an interventional pulmonologist, as we explore the nuances of deciding on fibrinolytic therapy (part 1) versus surgical management (part 2). Part 1: https://behindtheknife.org/podcast/clinical-challenges-in-thoracic-surgery-complex-pleural-effusions-empyema-part-1-of-2/ Learning Objectives: -Discuss the pros and cons of small bore versus large bore chest tubes for complex pleural effusions -Review the evidence for fibrinolytic therapy for management of complex pleural effusions -Describe the surgical management of a complex pleural effusion including VATS, open thoracotomy, empyema tube, Eloesser flap, and Clagett window -Create a framework for shared-decision making with patients regarding management of a complex pleural effusion Hosts: Kelly Daus MD, Peter White MD, Jed Gorden, MD and Brian Louie MD Referenced Material https://pubmed.ncbi.nlm.nih.gov/15745977/ Maskell NA, et al. First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005 Mar 3;352(9):865-74. doi: 10.1056/NEJMoa042473. Erratum in: N Engl J Med. 2005 May 19;352(20):2146. PMID: 15745977. https://pubmed.ncbi.nlm.nih.gov/21830966/ Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011 Aug 11;365(6):518-26. doi: 10.1056/NEJMoa1012740. PMID: 21830966. https://pubmed.ncbi.nlm.nih.gov/35830586/ Wilshire CL, et al. Comparing Initial Surgery versus Fibrinolytics for Pleural Space Infections: A Retrospective Multicenter Cohort Study. Ann Am Thorac Soc. 2022 Nov;19(11):1827-1833. doi: 10.1513/AnnalsATS.202108-964OC. PMID: 35830586. https://pubmed.ncbi.nlm.nih.gov/37043201/ Wilshire CL, et al. Effect of Intrapleural Fibrinolytic Therapy vs Surgery for Complicated Pleural Infections: A Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e237799. doi: 10.1001/jamanetworkopen.2023.7799. PMID: 37043201; PMCID: PMC10098968. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out more thoracic surgery episodes here: https://behindtheknife.org/podcast-category/cardiothoracic/

challenges md complex surgery clinical controlled pmid new england journal of medicine erratum vats pleural thoracic surgery jama netw open clagett jed gorden

Clinical Challenges in Thoracic Surgery: Complex Pleural Effusions & Empyema - Part 1 of 2